A major milestone for neuroClues: €10M Series A raised

neuroClues is proud to announce the closing of a €10M Series A financing round, bringing the company’s total funding raised to €25M.

This milestone marks a major step forward in our journey and validates a clear vision: transforming neurological assessment into a fast, objective, and scalable standard of care that can improve early diagnosis and patient outcomes worldwide.

Over the past 12 months, neuroClues has reached several strategic and clinical milestones that have significantly strengthened its position in the field of neurotechnology and digital health.

Among the most important achievements, neuroClues obtained CE certification (Class IIa) for its medical device, confirming its compliance with European medical standards and enabling broader clinical adoption across healthcare systems.

The company also accelerated its European expansion, with deployments now active in 7 countries across university hospitals, research centers, and neurology practices. This rapid adoption reflects a growing need from clinicians for more objective and quantitative tools in neurological examination.

At the clinical level, neuroClues is increasingly used by healthcare professionals to bring measurable data into neurological assessments, supporting decision-making with precision that was previously difficult to achieve in routine practice.

In parallel, neuroClues continues to build one of the most extensive clinical datasets in its field, enabling large-scale analysis and contributing to the early detection of neurodegenerative diseases such as Parkinson’s disease. This data-driven approach is a cornerstone of the company’s long-term mission in prevention and early diagnosis.

A key part of this progress is also the close collaboration with the Institut du Cerveau – Paris Brain Institute (ICM), where neuroClues has been integrated into several clinical cohorts, reinforcing the link between cutting-edge research and real-world medical application.

The Series A round is led by Teampact.ventures, White Fund SA, and the EIC Fund (European Investment Bank), with continued support from existing partners including invest.bw, LeanSquare, and Wallonie Entreprendre.

This combination of leading institutional investors and strong public support reflects growing confidence in the company’s approach and long-term vision.

In addition to institutional funding, neuroClues has also opened its capital to citizens through a campaign on Lita, which has already reached 90% of its target in just two weeks. This strong response demonstrates that the mission of neuroClues resonates far beyond the traditional medtech and venture ecosystem.

Looking ahead, neuroClues remains fully committed to its core mission:
making neurological assessment faster, more objective, and widely accessible, while shifting neurology toward earlier diagnosis and prevention — when interventions can still meaningfully change outcomes.

This Series A marks not an endpoint, but an acceleration phase.

🚀 It’s acceleration time.